Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Health
Chris Katje

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Cassava Sciences (NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.

Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock’s crash Sunday night.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.